Community-acquired pneumonia: similarities and differences between European and American guidelines - A narrative review –

José Barberán¹
Rubén Restrepo²
Pablo Cardinal-Fernández³

¹Internal Medicine Department, HM Montepríncipe University Hospital. Madrid, Spain.
San Pablo CEU University. Madrid, Spain.
²The University of Texas Health Science Center at San Antonio. Texas, USA
³Intensive Care Unit. HM Sanchinarro University Hospital. Madrid, Spain

ABSTRACT
Community-acquired pneumonia (CAP) is a severe disease. Early prescription of an adequate treatment has a positive impact in the CAP outcome. Despite the evidence of existing relevant differences between CAP across geographical areas, general guidelines can be designed to be applied everywhere. Eight years have passed between the publication of the European (EG) and American (AG) CAP guidelines, thus the aim of this narrative review is to compare both guidelines and summarize their recommendations. The main similarity between both guidelines is the antibiotics recommendation with the exception that AG mention new antimicrobials that were not available at the time of EG publication. Both guidelines recommend against routinely adding steroids as an adjuvant treatment. Finally, both guidelines acknowledge that the decision to hospitalize a patient is clinical and should be complemented with an objective tool for risk assessment. EG recommend the CRB-65 while AG recommend the Pneumonia Severity Index (PSI). EG and AG share a similar core of recommendations and only differ in minor issues such as new antibiotics. Likewise, both guidelines recommend against the routine prescription of steroids as an adjuvant therapy.

Key words: Community-Acquired Pneumonia; respiratory infections; European guidelines; American guidelines

Neumónia aguda comunitaria: similitudes y diferencias entre las guías Europeas y Americanas. Revisión narrativa
La neumonía adquirida en la comunidad (NAC) es una enfermedad grave. La prescripción temprana de un tratamiento adecuado ha demostrado mejorar el pronóstico de esta enfermedad. A pesar de que existen evidentes diferencias entre las NAC de acuerdo al área geográfica en la cual es diagnosticada, es posible realizar recomendaciones generales capaces de ser aplicadas en todo el mundo. Han pasado ocho años entre la publicación de las guías Europeas (GE) y Americanas (GA) de la NAC por lo cual el objetivo de la presente revisión narrativa es comparar ambas guías y resumir sus recomendaciones. La principal similitud entre ambas guías son las recomendaciones en los planes de antibioticos, con la diferencia que las GA mencionan a los nuevos antimicrobianos que no estaban disponible al momento de la publicación de GE. Ambas pautas recomiendan contra de la prescripción rutinaria de esteroides como tratamiento adyuvante. Finalmente, ambas guías reconocen que la decisión hospitalizar a un paciente es clínica, aunque debe complementarse con una herramienta objetiva para la evaluación de riesgos. Las GE recomiendan a la escala CRB-65 mientras que las GA al índice de severidad de la neumonía (PSI). En suma, ambas guías comparten la mayoría de las recomendaciones solo diferiendo en aspectos menores como los nuevos antibióticos. Ambas guías recomiendan en contra de la prescripción rutinaria de esteroides como terapia adyuvante.

PALABRAS CLAVE: Neumonía aguda comunitaria, infección respiratorias, guías Europeas de neumonía aguda comunitarias, guías Americanas de neumonía aguda comunitaria.
BACKGROUND

Community-acquired pneumonia (CAP) is a serious health threat due to its high rate of complications and mortality [1-5]. Clinical practice guidelines (CPG) emerged to improve quality of care and standardization of patients’ management [6]. Ideally, these documents should cover all aspects of a disease and support their recommendations with high quality evidence allowing physicians to make the best decision. For example, early prescription of an appropriate antimicrobial treatment can positively impact the CAP outcome [7]. Although, it is evident that exists relevant differences between CAP microbiology across geographical areas [8,9], it is also true that it is possible to identify general rules to be applied everywhere.

Continental and well accepted scientific societies regularly publish CAP CPG, in Europe the newest were published in 2011 [10] and in the United States during 2019 [11]. The aim of this narrative review is to compare both guidelines and summarize their recommendations.

SCOPE AND DEFINITIONS

The scope of European Guidelines (EG) is the management of adult patients with lower respiratory tract infections (LRTI). LRTI is defined as an acute illness (present for 21 days or less), usually with a cough, lower respiratory tract symptoms (sputum production, dyspnea, wheeze or chest discomfort/pain) and without an alternative explanation. In other words, LRTI is considered as an umbrella that can include patients with specific (for example acute bronchitis, influenza, exacerbation of chronic obstructive pulmonary disease [COPD], acute exacerbation of bronchiectasis [AEBX] and CAP) or non-specific respiratory entities. European guidelines provides two levels of certainty for the CAP definition, suspect ("an acute illness with cough and at least one of new focal chest signs, fever > 4 days or dyspnea/tachypnea, and without other obvious cause") or definitive (the previous definition but "supported by chest radiograph findings of lung shadowing that is likely to be new"). Conversely, the American guidelines (AG) are more restrictive and focus their recommendations only in adult and immunocompetent patients with radiologically confirmed CAP from United States, who have not completed foreign travels especially to regions with emerging respiratory pathogens [11].

Diagnosing a pneumonia is usually more complex than it appears, especially in overcrowded emergency departments. Traditional approaches include three basic categories: community, hospital and health-care associated pneumonia. The first and second term have been used for a long time; the third was previously described scenarios (vide supra).

CAP DIAGNOSIS AND MICROORGANISM IDENTIFICATION

In non-hospitalized patients suspected of having CAP (presence of at least one of the following clinical findings: new focal chest signs, dyspnea, tachypnea, pulse rate >100 or fever >4 days), EG propose to perform a serum-level of C-reactive protein (CRP). If the CRP level is lower than 20 mg/L at presentation and the symptoms have been present for more than 24 hours, the probability of having CAP is low. On the other hand, if the CRP level is higher than 100 mg/L, the probability is high. In the case of persisting doubt after CPR testing, a chest X-ray should be considered to confirm or reject the diagnosis.

Regarding the etiology, it was demonstrated that the proportion of causative microorganism isolated from CAP patients is 38%, despite the complexity or number of diagnose techniques applied. In most of the cases they are viruses (23%) followed by bacteria (11%), and fungi or mycobacteria (1%) [1].

Concerning tests for microorganism identification, both guidelines agree that they are not indicated in the out-patient setting. However, in those that require hospitalization the recommendations are the following (table 1):

- **Gram stain and culture of respiratory secretions.** The EG recommend obtaining sputum for Gram stain and culture when a purulent sample can be obtained and processed in timely manner. On the other hand, AG recommend these studies in the following situations: (a) in severe CAP (especially if they are intubated), (b) when an empirically treatment for methicillin-resistant *Staphylococcus aureus* (MRSA) or *Pseudomonas aeruginosa* will be performed, (c) when the patient has been infected with MRSA and/or *P. aeruginosa* (especially those with prior respiratory tract infection) or (d) in patients who were hospitalized and received parenteral antibiotics during the last 90 days.

- **Blood culture.** The EG recommend obtaining two set of blood culture in all patients that require hospitalization. Meanwhile, AG recommend only culture the blood in the four previously described scenarios (vide supra).

- **Streptococcus pneumoniae** urinary antigen. Traditional assays based on immunochromatographic membrane have a sensitivity and specificity of 75% and 95%, respectively [15,16]. However, new luminex-technology-based multiplex urinary antigen tests have achieved a sensitivity of 97-98% and a specificity of 100% for proven pneumococcal CAP [17]. The EG recommend detecting this antigen only in hospitalized patients and AG in the subgroup of hospitalized patients with severe CAP.

- **Legionella pneumophila** urinary antigen. This test has a sensitivity of 75% to 80% and a specificity of nearly 100% [18,19]. Recommendations for this test are similar to previous with the exception that is also recommended when there is an epidemiologic risk factor (e.g. *Legionella* outbreak or recent travel to a risky geographical region).
- **Influenza virus.** Traditional rapid influenza diagnostic tests have a sensitivity of 60% and a specificity of 98% [20]. Newer tests, based on rapid nucleic acid amplification, have increased their sensitivity to more than 90% maintaining the high specificity [21]. Both guidelines recommend detecting influenza and respiratory virus guided by epidemiological factors.

- **Mycoplasma pneumoniae and Chlamydia pneumoniae** (only mentioned in EG). Only use these tests when a high clinical suspicion of atypical agent exists and always associated with PCR techniques.

- **Invasive techniques** (only mentioned in EG). Thoracentesis should be performed in hospitalized patients with CAP when a significant pleural effusion is present. Bronchoscopic protected specimen brush, bronchoalveolar lavage and quantitative endotracheal aspirate should be the preferred technique in non-resolving pneumonia. Transthoracic needle aspiration can be considered only in exceptional circumstances of severely ill patients, with focal infiltrates in whom less invasive techniques have been non-diagnostic.
Determining where the patient should be treated requires answering two questions: should the patient be admitted to the hospital? and then, should the patient be considered for an intensive level of monitoring and treatment (e.g. intensive care unit [ICU], step-down or telemetry unit)? Every physician should always be aware that delay in ICU admission is an independent predictor of hospital mortality and longer length of stay [22,23]. Both guidelines acknowledge that the decision to hospitalize a patient is clinical. However, it should be complemented with objective tools for risk assessment. The EG recommend the CRB-65 while the AG recommend the Pneumonia Severity Index (PSI). Indeed, other factors exist in addition to clinical severity that should be considered at the moment of determining the need for hospital admission (e.g. inability to maintain oral intake, severe comorbid illness, impaired functions status, etc.) [7,24,25]. The EG recognized that biomarkers

| Table 2 | Comparison between empirical antibiotic recommendation in European and American guidelines for hospitalized patients with a community acquired pneumonia |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **European Guidelines – 2011** | **American Guidelines - 2019** |
| Non-severe CAP that require hospitalization without risk factors for *P. aeruginosa* or MRSA | (a) Combination therapy  
- Beta-lactam (penicillin G, aminopenicillin or aminopenicillin/ beta-lactamase inhibitor or ceftriaxone or cefotaxime) plus  
- Macrolide  
(b) Monotherapy  
- Non-antipseudomonal cephalosporin or respiratory fluoroquinolone (levofloxacin or moxifloxacin) or ertapenem (patients at risk of gram-negative enteric bacterium, particularly strains with extended-spectrum beta-lactamase, but without risk or after exclusion of *P. aeruginosa*) |
| (a) Combination therapy  
- Beta-lactam (ampicillin/sulbactam 1.5-3g every 6h, cefotaxime 1-2g every 8h, ceftriaxone 1-2g daily or ceftaroline 600mg every 12h) plus  
- Macrolide (azithromycin 500mg daily or clarithromycin 500mg every 12h) or doxycycline (100mg every 12h)  
(b) Monotherapy  
- Respiratory fluoroquinolone (levofloxacin 750mg daily or moxifloxacin 400mg daily) |
| Severe CAP that require hospitalization without risk factor for *P. aeruginosa* or MRSA | (a) Combination therapy  
- Non-antipseudomonal cephalosporins III plus  
- Macrolide  
(b) Monotherapy  
- Respiratory fluoroquinolone + non-antipseudomonal cephalosporins III |
| (a) Combination therapy  
- Antipseudomonal cephalosporin or acylureidopenicillin/ beta-lactamase inhibitor or carbapenem plus  
- Ciprofloxacin or macrolide + aminoglycoside (gentamicin, tobramycin or amikacin)  
a- Cefazidime has to be combined with penicillin G for coverage of *S. pneumoniae*.  
b- Meropenem preferred, up to 6 g possible, 3-2 in 3-h infusion  
c- Levofloxacin 750 mg/24 h or 500 mg twice daily is an alternative and also covers Gram-positive bacteria if treatment is empirical |
| (a) Combination therapy  
- Beta-lactam (ampicillin/sulbactam 1.5-3g every 6h, cefotaxime 1-2g every 8h, ceftriaxone 1-2g daily or ceftaroline 600mg every 12h) plus  
- Macrolide (azithromycin 500mg daily or clarithromycin 500mg every 12h) or doxycycline (100mg every 12h) |
| Severe CAP that require hospitalization with risk factor for *P. aeruginosa* | (a) Combination therapy  
- Antipseudomonal cephalosporin or acylureidopenicillin/ beta-lactamase inhibitor or carbapenem  
- Ciprofloxacin or macrolide + aminoglycoside (gentamicin, tobramycin or amikacin)  
a- Ceftazidime has to be combined with penicillin G for coverage of *S. pneumoniae*.  
b- Meropenem preferred, up to 6 g possible, 3-2 in 3-h infusion  
c- Levofloxacin 750 mg/24 h or 500 mg twice daily is an alternative and also covers Gram-positive bacteria if treatment is empirical |
| (a) Monotherapy  
- Antipseudomonal cephalosporin (cefpime 2g every 8h or ceftazidime 2g every 6h) or acylureidopenicillin/beta-lactamase inhibitor (piperacillin/tazobactam 4.5g every 6h), or carbapenem (imipenem 500mg every 6h or meropenem 1g every 6h) or aztreonam (2g every 8h) |
| CAP that require hospitalization with risk factor for MRSA | (a) Combination therapy  
- Tecomycin ± rifampin  
(b) Monotherapy  
- Tecomycin, linezolid or clindamycin (if susceptible) |
| (a) Monotherapy  
- Vancomycin (15mg/kg every 12h) or linezolid (600mg every 12h) |
(e.g. CRP or PCT) have a significant potential to improve assessment of severity, but have not been sufficiently evaluated to influence the hospitalization decision.

Regarding ICU admission, EG recommends admitting patients with acute respiratory failure, sepsis or septic shock, radiographic extension of infiltrate or severely decompensated comorbidities. The AG maintain the IDSA-2007 recommendation for ICU admission but also mention that SMART-COP (a score for identifying patients who need vasopressor support and/or mechanical ventilation) or SCAP (score for predicting the risk of adverse outcomes) score could be applied.

**ANTIMICROBIAL THERAPY**

In most of the cases, antimicrobial therapy should be empirical and consider agents against major micro-organisms that cause CAP as well as the patient’s features (e.g. presence of specific risk factor, allergies, intolerances, etc.). Regarding the micro-organisms, several observational data suggest that inpatient and outpatient CAP are caused by the same pathogens, except for *Legionella* and Gram-negative bacilli which are rarely documented in outpatient setting [11]. As bacterial pathogen often coexists with viruses and currently there is not a test accurate or fast enough to determine that the CAP is solely caused by a virus, AG recommend always empirically cover bacterial microorganism.

Comparison against antibacterial recommendation in EG versus AG can be appreciated in table 2. In addition, it is important to highlight that guidelines recommend initiating antimicrobial therapy as early as possible, within the first hour if the patient is in septic shock.

**Antibacterial therapy.** Although recommended antibacterial therapy is very similar in both guidelines, there are two main differences:

1. The AG recommend a list of antibiotics with a specific dose, meanwhile the EG limited their recommendation to the type of medication. In both cases, a list of possible antibiotics without any preference are reported. In 2017, the U.S. Healthcare Infections Control Practices Advisory Committee recommend that "when multiple therapeutic options are available, a hierarchy of antibiotics treatment recommendations should be provided with "first choice" options being those with adequate therapeutic efficacy, the lowest risk of facilitations antimicrobial resistance and the lowest risk of *C. difficile*..."[29]. The wide number, not hierarchical organized, options of antibiotics suggested by both guidelines have raised some concerns because they may not be in line with the previous statement[30]. Unfortunately, this problem seems difficult to be resolved in a short period of time because it is aroused by the fact that randomized clinical trials (RCTs) usually compare only two interventions, and a factorial RCT with all options is not feasible. Overall, almost all interventions are associated with high effectiveness for hard outcomes like mortality, thus conclusion about which is the best interventions should be drawn from weaker events like cure rate or frequency of side effects [31].

2. AG included ceftaroline as a beta-lactam to be combined with a macrolide (or respiratory fluoroquinolone in cases of severe CAP). At the time of EG publication, ceftaroline was not available. Ceftaroline is a fifth generation cephalosporin with a spectrum of activity similar to ceftriaxone but with an increased coverage over gram positive, particularly *S. pneumoniae* and *S. aureus* (MSSA and MRSA) [32]. Unfortunately, the evidence for recommending it, in severe patients (Fine V) or as a rescue therapy, is scarce as all RCTs that tested ceftaroline excluded this subgroup of patients [33–35]. Likewise, the AG recommend prescribing vancomycin or linezolid in case of risk factors for MRSA. A recommendation that is not well supported as ceftaroline has a good activity against MRSA as the benefit of this combination has not been demonstrated.

Although both guidelines consider the association of a beta-lactam with a macrolide or a respiratory fluoroquinolone at the same level for severe CAP without risk factors for MRSA and *P. aeruginosa*, the AG mentioned two meta-analysis based on observational studies that reported a benefit of macrolides over fluoroquinolones [36, 37].

Regarding patients with risk factors for *P. aeruginosa* and MRSA; three main scenarios could be possible. First, if the patient carried some of these microorganisms, the AG recommended to cover these micro-organisms regardless of the CAP severity. Second, if none of these micro-organisms were previously isolated but the CAP is severe, the plan of action should be obtaining cultures, starting empiric treatment with coverage for these microorganisms and deescalating if cultures are negative and the patient is stable (both conditions should be present). Finally, if none of the microorganisms were isolated but the CAP is not severe, cultures should be obtained and the coverage should be withheld until their results.

Regarding the duration of antibiotic therapy, both guidelines are relatively similar. The EG suggest at most 8 days in responder patients and the AG emphasize that shorter courses are as effective as longer courses. Thus, they recommend that the duration of antibiotics should be guided by the clinical response and a minimum of 5 days is necessary. Longer courses of antibiotics are recommended for pneumonia complicated by meningitis, bacteremia by *S. aureus*, endocarditis and other deep-seat infections or uncommon pathogens (eg. *Burkholderia pseudomallei*, *Mycobacterium tuberculosis* or endemic fungi).

**Other antibiotics.** AG guidelines mentioned two newest antibiotics, omadacycline and lefamulin. The former is a new amidomethylcycline antibiotic, derived from the tetracycline class that overcomes the efflux and ribosomal protection mechanisms of tetracycline resistance [38]. It has a high and sustained concentration in human pulmonary tissue and in vitro has activity against *S. pneumoniae, Haemophilus influenzae, S. aureus*, and atypical pathogens (*L. pneumophila, M. pneumoniae*, and *C. pneumoniae*)[39, 40]. The latter, is a new type of antibiotic denominated pleuromutilin. Lefamulin acts by binding to the peptidyl transferase center on the bacterial ribosome interfering with the protein production resulting in the inhibition of bac-
Community-acquired pneumonia: similarities and differences between European and American guidelines

J. Barberán, et al.
Rev Esp Quimioter 2021;34(2): 72-80

Antiviral therapy. The interest in virus as a pathogen in CAP has increased since its high prevalence was demonstrated [1]. The cornerstone of the treatment are anti-viral drugs, mainly neuraminidase inhibitors such as oseltamivir or zanamivir. The AG recommends antiviral treatment for all patients with positive influenza test, independent of illness duration and the severity of the disease (outpatients and inpatients). On the contrary, the EG suggests treating only if the duration of symptoms is less than 48 hours.

According to the AG, antiviral therapy should be always associated to standard antibacterial treatment (see below). However, the latter treatment could be discontinued after 48 or 72 hours if no evidence of bacterial infection was confirmed (negative cultures and antigens), PCT is low, and the patient is clinically stable.

ADJUVANT THERAPIES

Currently, it is well accepted that local and systemic host response is absolutely necessary for the CAP resolution. However, if this mechanism is dysregulated, it can lead severe entities (e.g. multiorgan dysfunction and respiratory failure) able to cause the patient death despite the micro-organism had been eradicated.

Steroids is one of the oldest interventions prescribed with the aim reduce the host response. Their prescription with the aim to improve the CAP outcome is not so clear and national societies have adopted opposite positions (e.g. British guidelines state that "... steroids are not recommended in the routine treatment of high severity CAP" while South African guidelines recommend "use of systemic corticosteroids should be considered in patients with severe CAP requiring intensive care unit (ICU) admission") [47, 48].

Resolving this contradiction is not only merely an academic exercise as this medication is associated with severe side effects such as hyperglycemia, hyperleukocytosis, increased rates of bleeding, secondary infection, etc. Although results from RCTs are inconclusive, or just improve soft outcomes [49-52], a recent meta-analysis reported that steroids could significantly decrease the mortality [53]. Both guidelines agree on not routinely recommending steroids in patients with CAP without septic shock or other disease that require steroids.

Macrolides have, in addition to their antimicrobial effect, several immunomodulatory properties (e.g. decrease the levels of proinflammatory cytokines such as IL-6 and increase levels of anti-inflammatory cytokines such as IL-10 as well as affect the structural cells of the respiratory tract that may modifying the migration of inflammatory cells to the lungs). Both guidelines usually recommend this type of antibiotics in association to a beta-lactam (vide supra).

Other interventions proposed for host response immunomodulation but not mentioned in EG or AG are:
- Vitamin C. Low concentrations of ascorbic acid in patients with sepsis are inversely correlated with the incidence of multiple organ failure and directly correlated with survival [54, 55].
- Aspirin. Observational studies have shown that the mortality owing to CAP is lower in patients using aspirin and that the combination of aspirin and macrolides improves survival in patients who present with septic shock owing to pneumonia [56].
- Immunoglobulins. The effect of this kind of molecules have been linked to the bacterial opsonization improvement, prevention of nonspecific complement activation, protection against antibiotic-induced endotoxin release, and neutralization of endotoxin and superantigens. Although two meta-analyses have shown a benefit of immunoglobulin use in patients with severe sepsis and septic shock [57, 58], a phase II study failed to demonstrate a significant difference in ventilator free day and mortality between a human polyclonal antibody preparation (trimodulin) and placebo groups. However, the post hoc analyses supported improved outcome regarding mortality with trimodulin in subsets of patients with elevated CRP, reduced IgM, or both [59].

CONCLUSIONS

Despite EG and AG were published with almost one decade of difference, both have more points in common than differences. In term of antibiotics recommendation, both are nearly similar with the difference that ceftaroline was included in the latter. Probably, in the near future, the availability of current antibiotics and molecular diagnosis test as well as the outbreak of new micro-organism (e.g. SARS-COV2) will determine an update of both guidelines.

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

REFERENCES

1. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. New Eng J Med. 2015;373(5):415-27. DOI:
15. Boulware DR, Daley CL, Merrifield C, Hopewell PC, Janoff EN. Rapid...tions. J Crit Care. 2005;128(6):3854-62. DOI: 10.1378/chest.128.6.3854

16. Sinclair A, Xie X, Telltscher M, Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol. 2013;51(7):2303-10. DOI: 10.1128/JCM.00137-13

17. Huijts SM, Pride MW, Vos JM, Jansen KU, Webber C, Gruber W, et al. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J. 2013;42(5):1283-90. DOI: 10.1183/09031936.00137412

18. Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle HD. Prevalence and diagnosis of Legionella pneumonia: a 3-year prospective study with emphasis on application of urinary antigen detection. J Infect Dis. 1990;162(6):1341-8. DOI: 10.1093/infdis/162.6.1341

19. Shimada T, Noguchi Y, Jackson JL, Miyashita J, Hayashino Y, Kamiya T, et al. Systematic review and meta-analysis: urinary antigen tests for Legionella tests for Legionellosis. Chest. 2009;136(6):1576-85. DOI: 10.1378/chest.08-2602

20. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156(7):500-11. DOI: 10.7326/0003-4819-156-7-20120430-00403

21. Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcripase Polymerase Chain Reaction: A Systematic Review and Meta-analysis. Ann Intern Med. 2017;167(6):394-409. DOI: 10.7326/M17-0848

22. Renaud B, Santin A, Corre F, Camus N, Van Peit D, Hayon J, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med. 2009;37(11):2867-74. DOI: 10.1097/CCM.0b013e3181c822fb

23. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137(3):552-7. DOI: 10.1378/chest.09-1547

24. Labaree J, Stone RA, Scott Obrosky D, Yealy DM, Meehan TP, Auble TE, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med. 2006;21(7):745-52. DOI: 10.1111/j.1525-1497.2006.00510.x

25. Marrie Tj, Huang JG. Low-risk patients admitted with community-acquired pneumonia. Am J Med. 2005;118(12):1357-63. DOI: 10.1016/j.amjmed.2005.06.035

26. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:527-72. DOI: 10.1086/511159

27. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin
28. Espana PP, Capelastegui A, Gorordo I, Esteban C, Orbé M, Ortega M, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249-56. DOI: 10.1164/rccm.200602-1770OC

29. [HICPAC] CDC/PHIPCAC. Antibiotics stewardship statements for antibiotics guidelines- recommendations of the Healthcare Infection Controls Practice Advisory Committee 2017 [Available from: https://www.cdc.gov/hicpac/pdf/antibiotic-stewardship-statement.pdf (accessed May 17,2020).]

30. Huttner B, Cappello B, Cooke G, Gandra S, Harbarth S, Imai M, et al. 2019 Community-acquired Pneumonia Treatment Guidelines: There Is a Need for a Change toward More Parsimonious Antibiotic Use. Am J Respir Crit Care Med. 2020;201(10):1315-6. DOI: 10.1164/rccm.201911-2268LE

31. Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert DN, et al. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis. 2008;47 Suppl 3:S249-65. PMC2827629

32. Kiang TK, Wilby KJ, Ensom MH. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of cefartoline. Clin Pharmacokinet. 2015;54(9):915-31. DOI: 10.1007/s40262-015-0281-3

33. File TM, Jr., Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of cefartoline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66 Suppl 3:i:ii19-32. DOI: 10.1093/jac/dkr096

34. Low DE, File TM, Jr., Eckburg PB, Talbot GH, David Friedland H, Lee J, et al. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of cefartoline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66 Suppl 3:i:ii33-44. DOI: 10.1093/jac/dkr097

35. Zhong NS, Sun T, Zhuo C, D’Souza G, Lee SH, Lan NH, et al. Cefartoline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161-71. DOI: 10.1016/S1473-3099(14)71018-7

36. Sigl WI, Asadi L, Euchir DT, Tjosvold I, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42(2):420-32. DOI: 10.1097/CCM.0b013e3182a6669b

37. Vardakas KZ, Trigkides KK, Falagas ME. Fluoroquinolones or macrolides in combination with beta-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis. Clin Microbiol Infect. 2017;23(4):234-41. DOI: 10.1016/j.cmi.2016.12.002

38. Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, et al. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother. 2015;59(11):7044-53. DOI: 10.1128/AAC.01536-15

39. Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6409-19. DOI: 10.1016/j.bmc.2016.07.029

40. Pfaffer MA, Rhomberg PR, Huband MD, Flamm RK. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis. 2018;90(2):143-7. DOI: 10.1016/j.diagmicrobio.2017.10.010

41. Alexander E, Goldberg L, Das AF, Moran GJ, Sandrock C, Gasink LB, et al. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. Jama. 2019. DOI: 10.1001/jama.2019.15468

42. Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013;57(9):4489-95. DOI: 10.1128/AAC.00358-13

43. Rodvold KA. Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother. 2019;74(Supplement_3):ii:ii2-ii:4. DOI: 10.1093/jac/dkz084

44. File TM, Jr., Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, et al. Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial. Clin Infect Dis. 2019;69(11):1856-1867. DOI: 10.1093/cid/ciz090

45. Stets R, Popescu M, Gonor J, Mitra I, Nseir W, Madej A, et al. Omadacycline for Community-Acquired Bacterial Pneumonia. New Engl J Med. 2019;380(6):517-27. DOI: 10.1056/NEJMoa1800201

46. Nicholson SC, Welte T, File TM, Jr., Strauss RS, Michiels B, Kaul P, et al. A randomised, double-blind trial comparing cefotibiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39(3):240-6. DOI: 10.1016/j.ijantimicag.2011.11.005

47. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:i:ii1-55. DOI: 10.1136/thx.2009.121434

48. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South African guideline for the management of community-acquired pneumonia in adults. J Thorac Dis. 2017;9(6):1469-502. DOI: 10.21037/jtd.2017.05.31

49. Conflanoieri M, Urbina R, Potena A, Piattella M, Parigi P, Puccio, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-8. DOI: 10.1164/rccm.200406-8080OC

50. Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Eviner N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(7):519-28. DOI: 10.7326/M15-0715
51. Torres A, Sibila O, Ferrer M, Pulverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. Jama. 2015;313(7):677-86. DOI: 10.1001/jama.2015.88

52. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511-8. DOI: 10.1016/S0140-6736(14)62447-8

53. Huang J, Guo J, Li H, Huang W, Zhang T. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(13):e14636. DOI: 10.1097/MD.0000000000014636

54. Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med. 1996;24(3):392-7. DOI: 10.1097/00003246-199603000-00006

55. Fowler AA, 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014;12:32. DOI: 10.1186/1479-5876-12-32

56. Falcone M, Russo A, Farcomeni A, Pieralli F, Vannucchi V, Vullo V, et al. Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination? Intensive Care Med. 2016;42(2):301-2. DOI: 10.1007/s00134-015-4139-9

57. Alejandria MM, Lansang MA, Dans LF, Mantaring JB, 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013(9):CD001090. DOI: 10.1002/14651858.CD001090.pub2

58. Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35(12):2677-85.

59. Welte T, Dellinger RP, Ebbert H, Ferrer M, Opal SM, Singer M, et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med. 2018;44(4):438-48. DOI: 10.1007/s00134-018-5143-7